TWD
NBIX icon

True Wealth Design’s Neurocrine Biosciences NBIX Stock Holding History

True Wealth Design’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179K Sell
1,064
-171
-14% -$25.4K 0.04% 133
2026
Q1 		$163K Buy
1,235
+270
+28% +$35.8K 0.05% 120
2025
Q4 		$137K Buy
965
+14
+1% +$2.03K 0.04% 130
2025
Q3 		$134K Buy
951
+609
+178% +$82.5K 0.04% 115
2025
Q2 		$43K Buy
342
+316
+1,215% +$36.2K 0.02% 222
2025
Q1 		$2.88K Sell
26
-418
-94% -$53K ﹤0.01% 879
2024
Q4 		$60.6K Sell
444
-148
-25% -$18.3K 0.02% 133
2024
Q3 		$68.2K Buy
592
+587
+11,740% +$80.5K 0.03% 88
2024
Q2 		$689 Buy
5
+2
+67% +$274 ﹤0.01% 598
2024
Q1 		$414 Buy
3
+1
+50% +$137 ﹤0.01% 666
2023
Q4 		$264 Hold
2
– – ﹤0.01% 635
2023
Q3 		$225 Hold
2
– – ﹤0.01% 617
2023
Q2 		$189 Hold
2
– – ﹤0.01% 658
2023
Q1 		$203 Hold
2
– – ﹤0.01% 727
2022
Q4 		$239 Buy
+2
New +$234 ﹤0.01% 636

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

True Wealth Design's NBIX Position: Q2 2026 in Review

True Wealth Design reduced its Neurocrine Biosciences (NBIX) stake by 14% in Q2 2026, selling an estimated $25.4K and leaving 1,064 shares worth $179K. The position accounts for 0.04% of the portfolio, ranked #133.

True Wealth Design first reported a position in NBIX in Q4 2022 and has held it in 15 quarters since. 108 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • True Wealth Design held 1,064 shares of Neurocrine Biosciences worth $179K as of Q2 2026.
  • True Wealth Design sold 171 Neurocrine Biosciences shares in Q2 2026, an estimated $25.4K.
  • Neurocrine Biosciences made up 0.04% of True Wealth Design's portfolio in Q2 2026, its #133 holding.
  • True Wealth Design first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 15 quarters since.
  • 108 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.